Taken together, these data suggest that there are increases in circulating MLKL in patients with NASH as severity of disease increases, but the concentrations, even in more severe NASH, tend to be lower in patients with NASH compared with AH. This evidence concerns the gene MLKL and metabolic dysfunction-associated steatohepatitis.